FindMyKOL
Clinical trialNCT03002805UnknownPhase 1Interventional

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

NCT03002805 is a phase 1 interventional trial sponsored by CBA Research. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies CBT-1® in Sarcoma. The registry lists an enrollment of 46 participants at 6 sites in 1 country. The registry lists a start date of 29 Mar 2018 and a primary completion date of 30 Sept 2020. 2 of its registered investigators have a FindMyKOL profile.

SponsorCBA Research →Enrollment46Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03002805
FieldValue
Registry IDNCT03002805
StatusUnknown
PhasePhase 1
Study typeInterventional trial
Lead sponsorCBA Research
Enrollment46
Registered sites6
Countries1
ConditionsSarcoma
DrugsCBT-1®
Start29 Mar 2018
Primary completion30 Sept 2020
Study completion30 Sept 2020
Last update posted19 Aug 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site, 1 recruiting
  • Sarcoma Oncology Research Center

    Santa Monica

    Sant P. Chawla, M.D.
    Recruiting
Florida, United States1 site, 1 recruiting
  • Mayo Clinic

    Jacksonville

    Steven Attia, D.O.
    Recruiting
Massachusetts, United States2 sites, 2 recruiting
  • Dana Farber Cancer Institute

    Boston

    Katherine Thornton, M.D.
    Recruiting
  • Massachusetts General Hospital

    Boston

    Gregory Cote, M.D., Ph.D.
    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • University of Pittsburgh Medical Center

    Pittsburgh

    Melissa Burgess, M.D.
    Recruiting
Washington, United States1 site, 1 recruiting
  • Seattle Cancer Care Alliance

    Seattle

    Lee Cranmer, M.D.
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 site, 1 recruitingWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 2 sites, 2 recruitingMA2Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 site, 1 recruitingPA1New JerseyNJConnecticutCTCalifornia: 1 site, 1 recruitingCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 site, 1 recruitingFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CBT-1®
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03002805

Each answer restates registry values shown on this page.

What is NCT03002805?

NCT03002805 is a phase 1 interventional trial sponsored by CBA Research. It studies CBT-1® in Sarcoma.

Where does NCT03002805 run?

The registry lists 6 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03002805 study?

The registered drug and biological interventions are CBT-1®.

When is NCT03002805 expected to complete?

The registry lists a primary completion date of 30 Sept 2020 and a study completion date of 30 Sept 2020. The sponsor last updated the record on 19 Aug 2019.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.